Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 4Not yet recruiting 2Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Genitourinary 4Other solid neoplasm 3Gastrointestinal 3Thoracic 2Tumor-Agnostic 1NET 1Head & Neck 1Endocrine 1Breast 1

Conditions

Uterine Cervical Neoplasms 2Thyroid Carcinoma, Anaplastic 1Thymoma 1Locally Advanced Cervical Cancer 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Paclitaxel 79Carboplatin 66pembrolizumab 61Bevacizumab 56Cisplatin 48Specimen Handling 29Drug Therapy 26Blood Specimen Collection 24Cyclophosphamide 20olaparib 19Taxes 17Magnetic Resonance Spectroscopy 16Letrozole 16Gemcitabine 16Biopsy 16liposomal doxorubicin 15niraparib 14fludarabine 14Brachytherapy 14Radiotherapy 13abemaciclib 12Topotecan 11Nivolumab 11Injections 11Doxorubicin 11lenvatinib 10Fluorouracil 10atezolizumab 9Surveys and Questionnaires 9Standard of Care 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × zimberelimab × Gynecologic × Clear all
NCT06790706 2025-10-06

IMMUNORARE5

Hospices Civils de Lyon

Phase 2 Recruiting
154 enrolled
EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
116 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06055738 2023-09-28

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Tang-Du Hospital

Phase 2 Recruiting
20 enrolled
Gynecologic

Locally Advanced Cervical Cancer

NCT05872724 2023-05-24

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Suzhou Municipal Hospital

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡